-
1
-
-
0035799806
-
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
-
DOI 10.1056/NEJM200105033441801
-
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350 (Pubitemid 32378388)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.18
, pp. 1343-1350
-
-
Tuomilehto, J.1
Lindstrom, J.2
Eriksson, J.G.3
Valle, T.T.4
Hamalainen, H.5
Ianne-Parikka, P.6
Keinanen-Kiukaanniemi, S.7
Laakso, M.8
Louheranta, A.9
Rastas, M.10
Salminen, V.11
Uusitupa, M.12
-
2
-
-
19244365650
-
Thiazolidinediones
-
Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118
-
(2004)
N Engl J Med
, vol.351
, pp. 1106-1118
-
-
Yki-Järvinen, H.1
-
3
-
-
0033754530
-
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
-
The Pioglitazone 001 Study Group
-
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-1611
-
(2000)
Diabetes Care
, vol.23
, pp. 1605-1611
-
-
Aronoff, S.1
Rosenblatt, S.2
Braithwaite, S.3
Egan, J.W.4
Mathisen, A.L.5
Schneider, R.L.6
-
4
-
-
33947134267
-
Thiazolidinediones and the risk of edema: A meta-analysis
-
DOI 10.1016/j.diabres.2006.09.010, PII S0168822706003949
-
Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007;76:279-289 (Pubitemid 46400130)
-
(2007)
Diabetes Research and Clinical Practice
, vol.76
, Issue.2
, pp. 279-289
-
-
Berlie, H.D.1
Kalus, J.S.2
Jaber, L.A.3
-
5
-
-
34648832073
-
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials
-
DOI 10.1016/S0140-6736(07)61514-1, PII S0140673607615141
-
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136 (Pubitemid 47464583)
-
(2007)
Lancet
, vol.370
, Issue.9593
, pp. 1129-1136
-
-
Lago, R.M.1
Singh, P.P.2
Nesto, R.W.3
-
6
-
-
0036852427
-
Peripheral edema
-
DOI 10.1016/S0002-9343(02)01322-0, PII S0002934302013220
-
Cho S, Atwood JE. Peripheral edema. Am J Med 2002;113:580-586 (Pubitemid 35379914)
-
(2002)
American Journal of Medicine
, vol.113
, Issue.7
, pp. 580-586
-
-
Cho, S.1
Atwood, J.E.2
-
7
-
-
33748748206
-
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
-
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
-
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105
-
(2006)
Lancet
, vol.368
, pp. 1096-1105
-
-
Gerstein, H.C.1
Yusuf, S.2
Bosch, J.3
Pogue, J.4
Sheridan, P.5
Dinccag, N.6
Hanefeld, M.7
Hoogwerf, B.8
Laakso, M.9
Mohan, V.10
Shaw, J.11
Zinman, B.12
Holman, R.R.13
-
8
-
-
57949115681
-
Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone
-
Ruaño G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL, Kocherla M, Holford TR, Petit WA, Hanks S. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta 2009;400:48-55
-
(2009)
Clin Chim Acta
, vol.400
, pp. 48-55
-
-
Ruaño, G.1
Bernene, J.2
Windemuth, A.3
Bower, B.4
Wencker, D.5
Seip, R.L.6
Kocherla, M.7
Holford, T.R.8
Petit, W.A.9
Hanks, S.10
-
9
-
-
53549106595
-
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists
-
Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, Ordway N, Dracopoli NC, Delmonte T, Hui L, Krishnan B, Cosma G, Ranade K. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. Pharmacogenet Genomics 2008;18:903-910
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 903-910
-
-
Geese, W.J.1
Achanzar, W.2
Rubin, C.3
Hariharan, N.4
Cheng, P.5
Tomlinson, L.6
Ordway, N.7
Dracopoli, N.C.8
Delmonte, T.9
Hui, L.10
Krishnan, B.11
Cosma, G.12
Ranade, K.13
-
10
-
-
33748742987
-
The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients
-
DOI 10.1210/jc.2006-0590
-
Hansen L, Ekstrøm CT, Tabanera Y, Palacios R, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist- induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006;91:3446-3450 (Pubitemid 44402117)
-
(2006)
Journal of Clinical Endocrinology and Metabolism
, vol.91
, Issue.9
, pp. 3446-3450
-
-
Hansen, L.1
Ekstrom, C.T.2
Tabanera, Y.P.R.3
Anant, M.4
Wassermann, K.5
Reinhardt, R.R.6
-
11
-
-
38449083331
-
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar
-
DOI 10.1097/FPC.0b013e3282f1b2d7, PII 0121301120071200000007
-
Spraggs C, McCarthy A, McCarthy L, Hong G, Hughes A, Lin X, Sathe G, Smart D, Traini C, Van Horn S, Warren L, Mosteller M. Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenet Genomics 2007;17:1065-1076 (Pubitemid 351339491)
-
(2007)
Pharmacogenetics and Genomics
, vol.17
, Issue.12
, pp. 1065-1076
-
-
Spraggs, C.1
McCarthy, A.2
McCarthy, L.3
Hong, G.4
Hughes, A.5
Lin, X.6
Sathe, G.7
Smart, D.8
Traini, C.9
Horn, S.V.10
Warren, L.11
Mosteller, M.12
-
12
-
-
0036234543
-
NFAT signaling: Choreographing the social lives of cells
-
DOI 10.1016/S0092-8674(02)00699-2
-
Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002;109(Suppl.):S67-S79 (Pubitemid 34457853)
-
(2002)
Cell
, vol.109
, Issue.2 SUPPL. 1
-
-
Crabtree, G.R.1
Olson, E.N.2
-
13
-
-
53149117031
-
Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway
-
Bao Y, Li R, Jiang J, Cai B, Gao J, Le K, Zhang F, Chen S, Liu P. Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway. Mol Cell Biochem 2008;317:189-196
-
(2008)
Mol Cell Biochem
, vol.317
, pp. 189-196
-
-
Bao, Y.1
Li, R.2
Jiang, J.3
Cai, B.4
Gao, J.5
Le, K.6
Zhang, F.7
Chen, S.8
Liu, P.9
-
14
-
-
0032540267
-
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
-
DOI 10.1016/S0092-8674(00)81573-1
-
Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin- dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228 (Pubitemid 28180855)
-
(1998)
Cell
, vol.93
, Issue.2
, pp. 215-228
-
-
Molkentin, J.D.1
Lu, J.-R.2
Antos, C.L.3
Markham, B.4
Richardson, J.5
Robbins, J.6
Grant, S.R.7
Olson, E.N.8
-
15
-
-
52049114958
-
NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure
-
Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heeneman S, Wehrens XH, De Windt LJ. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 2008;283:22295-22303
-
(2008)
J Biol Chem
, vol.283
, pp. 22295-22303
-
-
Bourajjaj, M.1
Armand, A.S.2
Da Costa Martins, P.A.3
Weijts, B.4
Van Der Nagel, R.5
Heeneman, S.6
Wehrens, X.H.7
De Windt, L.J.8
|